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Introduction
The Philadelphia (Ph) chromosome is one of the most fre-
quent cytogenetic abnormalities in adult acute lymphoblastic
leukemia (ALL). Its prevalence increases with age, accounting
for 12%-30% in patients aged 18-35 years, 40% in patients
aged 36-50 years, and over 50% in patients aged over 60
years.1,2 Philadelphia-positive (Ph+) ALL is associated with an
at least 10% lower rate of achieving a first complete remis-
sion (CR1) with standard induction as compared to Ph-nega-
tive disease and has poor long-term prognosis, with a median
survival of eight months.3,4 In recent years, BCR-ABL1-direct-
ed tyrosine kinase inhibitors (TKIs), such as imatinib mesy-
late (and more recently dasatinib or nilotinib), combined with
chemotherapy have been found to be very effective for induc-
ing disease remission in patients with Ph+ALL without addi-
tional toxicity, suggesting that better long-term outcomes
may be possible.5-10 In the pre-TKI era, allo-SCT was consid-
ered to be the standard of care using either a matched sibling
or unrelated donor in first CR (CR1) in adults.11-17 Although
allo-SCT could offer a curative option in Ph+ ALL,17 relatively
high rates of relapse and non-relapse mortality (NRM) limited
the benefit of an allo-SCT.15,18-20 The international Bone
Marrow Transplant Registry reported a leukemia-free sur-
vival (LFS) rate of 38% following human leukocyte antigen
(HLA)-identical allo-SCT in CR1.13 Several groups have report-
ed that TKI-based induction chemotherapy produced high
CR rates, thus allowing a high proportion of patients to pro-
ceed to allo-SCT.18,21-25 However, there is little information on
the efficacy of TKI administration after allo-SCT.26,27
Moreover, the impact of TKI-based therapy on long-term out-
come after allo-SCT remains unclear. To address whether
allo-SCT associated with TKI administration before and/or
after allo-SCT is a valid therapeutic approach as compared to
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This study aimed to determine the impact of tyrosine kinase inhibitors given pre- and post-allogeneic stem cell
transplantation on long-term outcome of patients allografted for Philadelphia chromosome-positive acute lym-
phoblastic leukemia. This retrospective analysis from the EBMT Acute Leukemia Working Party included 473 de
novo Philadelphia chromosome-positive acute lymphoblastic leukemia patients in first complete remission who
underwent an allogeneic stem cell transplantation using a human leukocyte antigen-identical sibling or human
leukocyte antigen-matched unrelated donor between 2000 and 2010. Three hundred and ninety patients received
tyrosine kinase inhibitors before transplant, 329 at induction and 274 at consolidation. Kaplan-Meier estimates of
leukemia-free survival, overall survival, cumulative incidences of relapse incidence, and non-relapse mortality at
five years were 38%, 46%, 36% and 26%, respectively. In multivariate analysis, tyrosine-kinase inhibitors given
before allogeneic stem cell transplantation was associated with a better overall survival (HR=0.68; P=0.04) and was
associated with lower relapse incidence (HR=0.5; P=0.01). In the post-transplant period, multivariate analysis
identified prophylactic tyrosine-kinase inhibitor administration to be a significant factor for improved leukemia-
free survival (HR=0.44; P=0.002) and overall survival (HR=0.42; P=0.004), and a lower relapse incidence (HR=0.40;
P=0.01). Over the past decade, administration of tyrosine kinase inhibitors before allogeneic stem cell transplan-
tation has significantly improved the long-term allogeneic stem cell transplantation outcome of adult Philadelphia
chromosome-positive acute lymphoblastic leukemia. Prospective studies will be of great interest to further con-
firm the potential benefit of the prophylactic use of tyrosine kinase inhibitors in the post-transplant setting.
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ABSTRACT
conventional chemotherapy, we conducted a retrospective
comparative study assessing the outcome of 473 adult
patients with Ph+ ALL who, between 2000 and 2010,
underwent allo-SCT in CR1 with HLA-identical siblings
or matched unrelated donors, with a special emphasis on
the impact of TKIs.
Methods
Study design, data collection and selection criteria
Patients with Ph+ ALL reported to the registry of the Acute
Leukemia Working Party of the European Group for Blood and
Marrow Transplantation (EBMT) were included in this study. For
the purpose of this specific analysis, participating centers were
requested to enroll consecutive Ph+ALL cases diagnosed between
January 2000 and December 2010. The study aimed to include
cases of Ph+ B-ALL receiving first allo-SCT from an HLA-identical
sibling donor (MSD) or HLA-matched unrelated donor (at least 6/6
HLA matching) (MUD) who: i) were aged 18 years or over at time
of transplant; ii) were in CR1; iii) were transplanted between 2000
and 2010; iv) received allogeneic unmanipulated bone marrow
(BM) or peripheral blood stem cells (PBSC) as stem cell source; v)
received a standard myeloablative conditioning (MAC) regimen or
a reduced-intensity conditioning (RIC) regimen according to
Bacigalupo’s criteria;28 and vi) whose complete clinical data and
outcomes were available. A total of 473 allo-SCT recipients from
77 participating centers met these eligibility criteria. Institutional
review board approval was obtained from all participating institu-
tions.
Minimal residual disease assessment
Investigators were asked to provide minimal residual disease
(MRD) data at time of transplant. As the most commonly accepted
level of sensitivity for a given sample to be considered PCR nega-
tive is 10-4 BCR/ABL copies, we distinguished two groups for the
purpose of this analysis: a “low-risk” group with MRD ≤10-4, and
a  “high-risk” group with a ratio >10-4.29,30 
Statistical analyses and definitions
The primary end points were leukemia-free survival (LFS),
relapse incidence (RI), and non-relapse mortality (NRM).
Secondary end points were overall survival (OS), acute graft-ver-
sus-host disease (aGvHD) and chronic graft-versus-host-disease
(cGvHD). 
Patient-related, disease-related, and transplant-related variables
were compared between the 2 groups receiving or not TKI before
transplantation using the χ2 statistics for categorical variables and
the Mann-Whitney test for continuous variables. Factors that dif-
fered significantly between the two groups with P values less than
0.05, and all factors associated with a P value less than 0.10 by uni-
variate analysis were included in the final models. Cumulative
incidence functions (CIF) were used to estimate RI and NRM in a
competing risk setting, because death and relapse compete with
each other. To study cGvHD, we considered relapse and death to
be competing events. Probabilities of LFS and OS were calculated
using Kaplan-Meier estimates. Univariate analyses were per-
formed using Gray’s test for CIF and the log rank test for LFS and
OS. Associations of patients’ and graft characteristics with out-
comes were evaluated in multivariate analysis, using Cox propor-
tional hazards model. In order to assess the possible impact of
acute GvHD, chronic GvHD and use of up-front prophylactic TKI
after transplant on outcome, we used a Cox model with time-
dependent variables. 
All tests were two-sided. The type-1 error rate was fixed at 0.05
for determination of factors associated with time-to-event out-
comes. Statistical analyses were performed with SPSS 19 (SPSS
Inc./IBM, Armonk, NY, USA) and R 3.0.1 (R Development Core
Team, Vienna, Austria) software packages.
Results
Patients’ characteristics
Four hundred and seventy-three allo-SCT recipients
were included in this study (Online Supplementary Table
S1); 260 (55%) were males. Median age was 42 years
(range 18-70). Sixty-nine (15%) patients presented with
extramedullary disease at time of diagnosis and the medi-
an white blood cell (WBC) count was 20.9x109/L (range
0.3-640). Three hundred and seventy-five (79.3%) patients
received a standard MAC regimen and 98 (20.7%) an RIC
regimen. One hundred and fifty-five (33.3%) patients
received antithymocyte globulin (ATG) as part of the con-
ditioning regimen. The median follow up (F/U) of alive
patients after allo-SCT was 45 months.
Tyrosine kinase treatment features
Three hundred and ninety (82.5%) patients received
TKIs before transplant. Among them, 329 received TKIs at
induction, 274 at consolidation, 100 at induction only, 61
at consolidation only, 213 both at induction and consolida-
tion. For 16 patients who received TKIs at induction, infor-
mation at consolidation was missing. As expected, ima-
tinib was the most widely used TKI (89.1%) at a median
dose of 600 mg/d, followed by dasatinib (9.3%) at a medi-
an dose of 140 mg/d, while 6 patients received nilotinib (3
unknown cases). The median time of TKI initiation was
11 days (range 0-363) after diagnosis and median duration
of administration was 99 days (range 7-385). The groups
“TKIs before allo-SCT” and “no TKIs before allo-SCT”
were comparable in terms of age, WBC at diagnosis, inter-
val from diagnosis to CR1 and from CR1 to HSCT, patient
sex, donor sex, extramedullary disease at diagnosis, type
of donor, and level of MRD (Online Supplementary Table
S1). Median follow up of patients without TKIs before
allo-SCT and with TKIs before transplant were 98 months
(range 1-142) and 42 months (range 1.2-145), respectively
(P<0.0001). The two groups were also different in terms of
stem cell source: PBSC was given to 309 patients (79%) in
the group with TKIs versus 55 patients (66%) in the group
without TKIs (P=0.01). More patients received MAC regi-
men in the group without TKIs before allo-SCT (96% vs.
76%; P=0.001).
Finally, 157 patients received TKIs after transplant at a
median of 83 days (range 0-1786) after transplant: 124
received imatinib, 26 dasatinib, 1 nilotinib, and 6 missing
cases. In all, 60 patients received TKIs post transplant for
primary prophylaxis of relapse.  
Outcome 
At five years, OS of the whole population was 46%
(95%CI: 41-51). In univariate analysis, TKIs before trans-
plant was the only factor associated with better OS [47%
(95%CI: 41-53) vs. 38% (95CI: 27-48) in patients not
receiving TKIs before allo-SCT, respectively; P=0.04]
(Table 1 and Figure 1). As aGvHD, cGvHD and TKI post
transplant were considered as a time-dependent variable,
HR and 95%CI can only be estimated by using Cox model
with time-dependent variable (Online Supplementary Table
S2). In multivariate analysis for OS, 2 factors were favor-
able factors: TKI administration before allo-SCT
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(HR=0.68; 95%CI: 0.47-0.98; P=0.04), and TKIs given post
transplant in prophylaxis of relapse (HR=0.42; 95%CI:
0.23-0.76; P=0.004) whereas older age of the patient, a
longer interval from diagnosis to transplant, and aGvHD II
or over were unfavorable factors (HR=1.02, 95%CI: 1.00-
1.03, P=0.01; HR=1.002, 95%CI: 1.001-1.004, P=0.001;
HR=1.43, 95%CI: 1.05-1.94, P=0.02, respectively). 
Overall LFS at five years was 38% (95%CI: 0.34-0.43).
In univariate analysis, higher WBC at diagnosis was signif-
icantly associated with lower LFS [30% (95%CI: 23-37) vs.
44% (95%CI: 37-50); P=0.014]. Multivariate analysis for
LFS identified 2 favorable factors: MUD (HR=0.65;
95%CI: 0.46-0.92; P=0.014) and, interestingly, TKIs given
post transplant (HR=0.44; 95%CI: 0.26-0.74; P=0.002)
(Table 2). Higher WBC at diagnosis and longer interval
from diagnosis to transplant were associated with lower
LFS (HR=1.002, 95%CI: 1.000-1.003, P=0.01, and
HR=1.002, 95%CI: 1.001-1.003, P=0.003, respectively).
In this cohort, 94 (40%) patients died from disease
relapse, with a cumulative incidence of relapse of 36%
(95%CI: 0.32-0.41) at five years. In univariate analysis, the
cumulative incidence of RI in the group of patients with
TKIs before allo-SCT was 33% (95%CI: 28-38) versus 50%
(95%CI: 38-60) in the group with no TKIs before trans-
plant (P=0.006) (Figure 1). In multivariate analysis, use of
TKIs before transplant (HR=0.56; 95%CI: 0.36-0.87;
P=0.01) and the type of donor (MUD vs. MSD) (HR=0.47;
95%CI: 0.30-0.75; P=0.001) were the 2 significant protec-
E. Brissot et al.
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Table 1. Univariate analysis for pre-allo-SCT factors at five years.
5 year results N LFS (95% CI) OS  (95% CI) RI (95% CI) NRM (95% CI)
Patient age <median 41% [34-48] 50% [42-56] 35% [29-41] 23% [17-29]
>median 35% [28-41] 42% [34-49] 37% [30-43] 28% [22-34]
P 0.1 0.09 0.52 0.18
Interval diagnosis to CR1 <median 40% [33-47] 48% [40-55] 35% [28-41] 25% [19-30]
>median 36% [29-43] 44% [36-51] 38% [31-45] 25% [19-31]
P 0.47 0.39 0.58 0.65
Interval CR1 to allo-SCT <median 39% [32-45] 48% [40-54] 39% [32-45] 22% [16-27]
>median 38% [31-44] 44% [36-51] 34% [27-40] 28% [22-34]
P 0.77 0.68 0.22 0.09
Interval diagnosis to allo-SCT <median 39% [32-45] 49% [42-56] 37% [31-43] 23% [18-29]
>median 37% [30-43] 42% [35-50] 35% [28-41] 28% [22-34]
P 0.76 0.52 0.57 0.28
Donor type HLA identical 234 36% [29-42] 45% [37-52] 43% [36-49] 20% [15-26]
MUD 249 40% [33-46] 47% [39-53] 30% [23-35] 30% [24-36]
P 0.08 0.69 0.0004 0.09
Conditioning regimen MAC 375 38% [33-43] 47% [41-52] 34% [28-39] 28% [22-32]
RIC 98 38% [28-48] 39% [24-53] 44% [33-53] 18% [14-22]
P 0.27 0.54 0.01 0.14
Extramedullary disease No 372 38% [32-43] 47% [41-52] 36% [30-41] 26% [21-30]
Yes 69 39% [26-50] 45% [32-57] 41% [28-52] 21% [16-25]
P 0.87 0.95 0.3 0.21
TKIs before transplantation No 83 31% [20-40] 38% [27-48] 50% [38-60] 20% [11-28]
Yes 390 40% [34-44] 47% [41-53] 33% [28-38] 27% [18-37]
P 0.06 0.04 0.006 0.27
MRD at transplant Negative 255 40% [34-47] 48% [40-55] 35% [28-41] 25% [19-30]
Positive 140 40% [31-48] 48% [39-56] 35% [27-43] 24% [19-30]
P 0.99 0.82 0.76 0.79
Female donor to male R No 386 39% [33-44] 47% [41-52] 36% [31-41] 25% [20-29]
Yes 87 37% [25-47] 43% [31-54] 36% [26-46] 27% [22-31]
P 0.96 0.65 0.95 0.72
WBC at diagnosis <median 44% [37-50] 48% [41-55] 30% [24-36] 26% [20-31]
>median 30% [23-37] 43% [35-50] 44% [36-51] 25% [20-31]
P 0.009 0.24 0.0009 0.63
Stem cell source BM 109 38% [29-47] 46% [35-55] 36% [26-44] 26% [17-34]
PBSC 364 38% [32-43] 46% [39-51] 36% [30-41] 26% [18-34]
P 0.81 0.62 0.84 0.89
Patient sex male 260 38% [31-44] 44% [37-51] 37% [31-43] 25% [19-30]
female 213 38% [31-45] 49% [41-56] 35% [28-41] 27% [21-32]
P 0.83 0.73 0.58 0.53
ATG NO 310 37% [31-43] 45% [38-51] 37% [31-42] 25% [20-30]
YES 155 38% [29-46] 48% [38-56] 35% [27-43] 27% [21-32]
P 0.62 0.68 0.29 0.68
LFS: leukemia-free survival; OS: overall survival; RI: relapse incidence; NRM: non-relapse mortality; CR1: first complete remission; HLA: human leukocyte antigen; MUD: matched
unrelated donor; MAC: myeloablative conditioning; RIC: reduced intensity conditioning; TKIs: tyrosine kinase inhibitors; MRD: minimal residual disease; WBC: white blood cells; BM:
bone marrow; PBSC: peripheral blood stem cells; ATG: antithymocyte globulin.
tive factors against relapse. Two other “post transplant”
factors were associated with lower RI in multivariate
analysis: TKIs post transplant in prophylaxis (HR=0.40;
95%CI: 0.21-0.76; P=0.01) and aGvHD grade II or over
(HR=0.45; 95%CI: 0.29-0.71; P=0.001). The use of an RIC
regimen (HR=1.69; 95%CI: 1.08-2.65; P=0.02) and higher
WBC at diagnosis (HR=1.003; 95%CI: 1.002-1.005;
P=0.0002) remained a significant risk factor for higher RI. 
Cumulative incidence of NRM was 26% (95%CI: 0.22-
0.30) at five years. Sixty-six (28%) patients died from
GvHD, 37 (15.7%) from infections and 8 (3.4%) from
veno-occlusive disease. In uni- and multivariate analysis,
the use of TKIs before allo-SCT did not influence NRM
after transplant [27% (95%CI_18-37) in patients who
received TKIs vs. 20% (95%CI: 11-28) in patients without
TKIs; P=0.27]. Besides, in univariate analysis, no factor
was significantly associated with NRM. In multivariate
analysis, aGvHD and cGvHD were unfavorable factors for
NRM (HR=2.22; 95%CI: 1.45-3.39; P=0.00003 and
HR=3.32; 95%CI: 1.90-5.82; P<10-4, respectively) as well
as age at transplant and time from diagnosis to transplant.
Impact of minimal residual disease on outcome
In this study, 395 patients were evaluated for MRD at
time of transplant. MRD was determined by RT-PCR in
344 patients (93%), and by flow cytometry in 26 (7%)
patients (25 missing cases). The median time for MRD
evaluation prior to transplant was 16 (range 0-80) days.
Two hundred and fifty-five (65%) had an MRD of 10-4 or
under and 140 patients (35%) had an MRD at transplant
over 10-4. Interestingly, there were no statistically signifi-
cant differences in terms of OS, LFS, RI and NRM at five
years between the “low-risk” and the “high-risk” MRD
groups: LFS, 40% (95%CI: 34-47) versus 40% (95%CI: 31-
48) (P=0.99); OS, 48% (95%CI: 40-55) versus 48%
(95%CI: 39-56, %±4) (P=0.82), RI: 35% (95%CI: 28-41)
versus 35% (95%CI: 27-43) (P=0.76); and NRM, 25%
(95%CI: 19-41) versus 24% (95%CI: 19-30)  (P=0.79),
respectively. Also, no correlation was found between use
of TKIs before transplant and MRD level at transplant
(P=0.17).
Graft-versus-host disease 
The cumulative incidence of grade 2-4 aGvHD at 100
days and cGvHD at five years were 40%±2 and 53%±2,
respectively. In univariate analysis, the use of TKIs pre-
transplant was significantly associated with a higher rate
of aGvHD grade II+ [37% (95%CI: 31%-41%) vs. 24%
(95%CI: 15%-34%); P=0.04] and of cGvHD [56%
(95%CI: 50%-60%) vs. 37% (95%CI: 25%-48%)
(P=0.008)] (Table 3). As TKIs post transplant was consid-
ered as a time-dependent variable, HR and 95%CI can
only be estimated by using Cox model with time-depen-
dant variable and are indicated in Online Supplementary
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Figure 1. Probability of (A) leukemia-free survival (LFS), (B) overall survival (OS), (C) relapse incidence (RI), and (D) non-relapse mortality (NRM)
in allografted patients with Ph+ALL in first complete remission  with TKIs before allogeneic stem cell transplantation versus without TKIs
before allogeneic stem cell transplantation.  
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Table S3. However, in multivariate analysis, the use of TKI
before transplant after allo-SCT, studied as a time-depen-
dant variable, was not associated with aGvHD or cGvHD,
although TKIs post transplant was significantly associated
with lower cumulative incidence of aGvHD (HR=0.21;
95%CI: 0.05-0.85; P=0.03). ATG was a protective factor of
cGvHD (HR=0.57; 95%CI: 0.40-0.82; P=0.002).
Discussion
This study confirms that TKIs are a critical treatment
component for patients with adult Ph+ALL in whom an
allo-SCT is indicated. We found a significantly superior 5-
year post-transplant OS due to lower relapse rates in
patients who received TKIs before allo-SCT. It is clear that
inclusion of imatinib and newer TKIs into the various
phases of the treatment of Ph+ ALL has re-shaped the ther-
apeutic algorithm. Thomas et al.31 showed that the associ-
ation of imatinib with induction chemotherapy resulted in
a 2-year OS reaching 56%, including the group of patients
who proceeded to standard MAC allo-SCT. Another sin-
gle center study showed that incorporation of imatinib
into induction chemotherapy with subsequent allo-SCT
after MAC achieved a 3-year OS rate of 78%.22 In a small-
er series of 25 patients with Ph+ ALL in CR1 who received
post-transplant imatinib, the 3-year OS reached 62%.32
Although several earlier studies suggested a benefit for
including TKIs in the treatment of Ph+ ALL, evidence of a
long-term survival benefit has only become available more
recently because many of the initial studies concerned
early data with short-term follow up. The Japanese Adult
Leukaemia Study Group recently reported a higher 3-year
OS probability of 65% when combining imatinib-based
induction and MAC allo-SCT.33 However, many of these
studies included a significant proportion (up to 39%) of
untransplanted patients. Our current study is the largest
patient group yet reported to receive allo-SCT in Ph+ ALL
in CR1 in the era of TKIs, with a long-term follow up at
five years post allo-SCT. The use of pre-transplant TKIs
had the beneficial effect in that all patients were in CR1
before allo-SCT.  This is consistent with other observa-
tions that TKIs enhance the feasibility of allo-SCT for
Ph+ALL by increasing remission rates and extending
remission durations.17,18,23,25,31,34-38 In this study, pre-trans-
plant TKI use was an independent variable in multivariate
analysis for improving long-term OS in patients trans-
planted in CR1. This superior OS appeared to be largely
related to a lower rate of relapse. Indeed, pre-transplant
TKIs were associated with lower RI in both uni- and mul-
tivariate analyses. Consistent with other reports, we
found that the use of TKIs before transplant was not asso-
ciated with increased NRM.27 
In this study, the MRD level at transplant was not pre-
dictive for outcome, and did not correlate with TKI treat-
ment. Reports from the pre-imatinib era suggested a close
correlation between BCR-ABL transcript levels and out-
come.39,40 In the TKI era, BCR-ABL transcript levels have
also been correlated with response in some studies.41
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Table 2. Multivariate analysis of leukemia-free survival, overall survival, reduced intensity and non-relapse mortality at 5 years.
LFS OS RI NRM
Variable HR P HR P HR P HR P
95%CI 95%CI 95%CI 95%CI
TKIs before transplant 0.72 0.06 0.68 0.04 0.56 0.01 1.01 0.97
0.51-1.01 0.47-0.98 0.36-0.87 0.57-1.80
Age at transplant (years) 1.01 0.13 1.02 0.01 1.00 0.86 1.02 0.01
1.00-1.02 1.00.-1.03 0.99-1.02 1.01-1.04
WBC at diagnosis>median 1.002 0.01 1.000 0.77 1.003 0.0002 0.999 0.62
1.000-1.003 0.999-1.002 1.002-1.005 0.996-1.002
Interval from diagnosis 1.002 0.003 1.002 0.001 1.001 0.21 1.002 0.003
to transplant 1.001-1.003 1.001-1.004 0.999-1.003 1.001-1.004
Female R vs.male R 1.01 0.95 0.89 0.48 0.98 0.93 1.16 0.52
0.75-1.35 0.65-1.23 0.67-1.45 0.74-1.83
Female D to male R 0.87 0.49 0.97 0.90 0.75 0.26 1.09 0.79
0.59-1.29 0.65-1.47 0.45-1.25 0.60-1.97
MUD vs. MSD 0.65 0.014 0.81 0.27 0.47 0.001 1.13 0.65
0.46-0.92 0.56-1.18 0.30-0.75 0.67-1.91
RIC vs. MAC 1.14 0.48 0.95 0.78 1.69 0.02 0.56 0.07
0.80-1.62 0.64-1.40 1.08-2.65 0.29-1.06
ATG 1.19 0.31 1.05 0.78 1.26 0.33 1.07 0.79
0.85-1.68 0.73-1.52 0.79-2.01 0.65-1.77
TKIs post-transplant in prophylaxis* 0.44 0.002 0.42 0.004 0.40 0.01 0.46 0.08
0.26-0.74 0.23-0.76 0.21-0.76 0.20-1.10
Acute GvHD≥II* 0.94 0.67 1.43 0.02 0.45 0.001 2.22 0.0003
0.71-1.25 1.05-1.94 0.29-0.71 1.45-3.39
Chronic GvHD* 1.28 0.15 1.09 0.62 0.65 0.08 3.32 0.0000
0.92-1.78 0.78-1.53 0.40-1.05 1.90-5.82
CR1: first complete remission; HLA: human leukocyte antigen; MSD: matched sibling donor; MUD: matched unrelated donor; MAC: myeloablative conditioning; RIC: reduced intensity
conditioning; TKIs: tyrosine kinase inhibitors; WBC: white blood cells; BM: bone marrow; PBSC: peripheral blood stem cells; ATG: antithymocyte globulin; GvHD: graft-versus-host dis-
ease; R: recipient; D: donor.  *Time-dependant variable.
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However, long-term outcome in relation to BCR-ABL
response to any given therapeutic intervention is difficult
to interpret. Unlike chronic myeloid leukemia, there is no
clear agreement on what represents a therapeutically
important BCR-ABL response at a given time point during
Ph+ ALL therapy. Lee et al.20 showed that a 3-log reduction
in BCR-ABL transcripts after one month of imatinib treat-
ment predicted a reduced risk of relapse. In contrast,
Yanada et al.42 observed no association between rapid
achievement of BCR-ABL negativity and long-term out-
come. In the present study, a 0.01% threshold was used to
define MRD positivity, as widely used.43,44 However, using
this threshold, we found no association between the MRD
level before transplant and allo-SCT outcome. Several fac-
tors may account for this negative finding. First, despite
some standardization in monitoring BCR-ABL fusion tran-
scripts, this registry-based study included diverse method-
ologies for MRD determination. However, MRD was
determined mainly by PCR for detection of chimeric
mRNA arising from BCR-ABL1 genomic recombination in
344 patients (93%). This assay has been widely used to
monitor response and guide therapeutic choices.20,40,42 Our
results are quite consistent with two recently published
studies. Schultz et al. reported 5-year outcomes of imatinib
plus intensive chemotherapy in 91 children (age 1-21
years) with and without allogeneic BMT. MRD levels at
the end of the second consolidation also did not predict
outcome in those patients receiving either an unrelated or
related donor BMT from all cohorts with 77±13% 5-year
EFS for MRD 0.01% or under (n=14) compared with
40±22% for MRD over 0.01% (n=5; P=0.18).45 Bachanova
et al. reported the outcome of 197 Ph+ALL patients who
underwent allo-SCT. MRD before transplant, in the whole
cohort, as determined by FISH and/or PCR, had no impact
on relapse (P=0.13), disease-free survival (P=0.56) or over-
all survival (P=0.66). In sub-group analysis, patients receiv-
Table 3. Univariate analysis for acute graft-versus-host disease and chronic graft-versus-host disease at five years.
Variable                                                                                                   aGvHD grade≥2                                                     5y cGvHD
Patient age                                                              <median                                           35% [28-40]                                                                   56% [48-63]
                                                                                  >median                                           34% [27-39]                                                                   49% [42-56]
                                                                                         P                                                          0.59                                                                                  0.25
Interval diagnosis to CR1                                    <median                                           35% [28-41]                                                                   55% [47-61]
                                                                                  >median                                           32% [26-38]                                                                   50% [42-56]
                                                                                         P                                                          0.58                                                                                  0.19
Interval CR1 to allo-SCT                                      <median                                           32% [25-38]                                                                   54% [46-61]
                                                                                  >median                                           35% [29-41]                                                                   51% [43-57]
                                                                                         P                                                          0.35                                                                                  0.63
Interval diagnosis to allo-SCT                            <median                                           35% [28-40]                                                                   54% [46-60]
                                                                                  >median                                           33% [27-39]                                                                   51% [44-57]
                                                                                         P                                                          0.82                                                                                  0.40
Donor type                                                                  MSD                                               33% [26-39]                                                                   51% [43-57]
                                                                                      MUD                                               35% [29-41]                                                                   55% [47-61]
                                                                                         P                                                          0.43                                                                                  0.34
Conditioning                                                               MAC                                               35% [30-4]]                                                                   55% [49-60]
                                                                                       RIC                                                30% [21-4]]                                                                   43% [31-53]
                                                                                         P                                                          0.16                                                                                  0.07
Extramedullary disease                                            No                                                 35% [30-40]                                                                   55% [48-59]
                                                                                       Yes                                                27% [16-37]                                                                   44% [30-57]
                                                                                         P                                                          0.13                                                                                  0.36
TKIs before transplantation                                     No                                                 24% [15-34]                                                                   37% [25-48]
                                                                                       Yes                                                37% [31-41]                                                                   56% [50-61]
                                                                                         P                                                          0.04                                                                                 0.008
MRD at transplant                                                 Negative                                            35% [28-40]                                                                   54% [46-60]
                                                                                   Positive                                            34% [26-42]                                                                   51% [42-60]
                                                                                         P                                                          0.91                                                                                  0.46
Female donor to male R                                           Yes                                                35% [29-39]                                                                   50% [44-55]
                                                                                        No                                                 32% [21-41]                                                                   63% [50-72]
                                                                                    p-value                                                    0.50                                                                                  0.13
WBC at diagnosis  x 109/L                                    <median                                           33% [27-39]                                                                   56% [49-62]
                                                                                  >median                                           35% [28-42]                                                                   49% [40-56]
                                                                                         P                                                          0.65                                                                                  0.11
Stem cell source                                                        BM                                                37% [28-46]                                                                   46% [34-56]
                                                                                      PBSC                                               33% [28-38]                                                                   55% [48-6]]
                                                                                    p-value                                                    0.36                                                                                  0.21
Sex                                                                                male                                               34% [28-39]                                                                   56% [49-62]
                                                                                    female                                             34% [27-40]                                                                   48% [40-55]
                                                                                         P                                                          0.88                                                                                  0.16
ATG                                                                                NO                                                35% [29-40]                                                                   56% [50-62]
                                                                                      YES                                                33% [25-40]                                                                   45% [35-53]
                                                                                        P                                                          0.84                                                                                  0.09
cGvHD: chronic graft-versus-host disease; CR1: first complete remission; HLA: human leukocyte antigen; MUD: matched unrelated donor; MAC: myeloablative conditioning; RIC:
reduced intensity conditioning; TKIs: tyrosine kinase inhibitors; MRD: minimal residual disease; WBC: white blood cells; BM: bone marrow; PBSC: peripheral blood stem cells; 
ATG: antithymocyte globulin. 
ing pre-HCT TKI in combination with MRD negativity
pre-RIC HCT had superior OS (55%) compared with a
similar MRD population after MAC (33%; P=0.0042).46 In
our study, the number of patients in the RIC group who
did not receive TKIs before allo-SCT (n=6) did not allow a
subgroup analysis to be made. We can also hypothesize
that, since TKIs induce profound molecular responses, a
lower cutoff might have been more informative for corre-
lating MRD with outcome. The lower relapse incidence
seen in patients given pre-transplant TKI probably reflect-
ed a more profound molecular response in this patient
group. It is also possible that post-transplant interventions
with TKIs controlled  allo-SCT patients with a higher
MRD load until the development of the immune-mediat-
ed graft-versus-leukemia (GvL) effect. MRD monitoring of
BCR-ABL fusion-transcript after allo-SCT for Ph+ ALL
could shed some light on this possibility.47
The issue of whether, and under what circumstances,
TKIs should be administered after allo-SCT remains unre-
solved. We found a significant benefit of prophylactic TKIs
on LFS, OS and RI. Study design prevented a full analysis
of treatment and tolerability of TKI administration post
allo-SCT. However, previous data suggest that a relatively
short exposure to TKIs may control residual leukemia prior
to the establishment of a GvL effect. Pfeifer et al.30 recently
compared prophylactic with MRD-triggered imatinib after
allo-SCT for Ph+ ALL. Prophylactic imatinib significantly
reduced the incidence of molecular recurrence after allo-
SCT compared with MRD-triggered imatinib (40% vs.
69%; P=0.046). Interestingly, 5-year survival in both inter-
ventional groups was high (80% and 74.5%), despite pre-
mature discontinuation of imatinib in the majority of
patients because of poor tolerability. Ram et al.32 reported
that imatinib, given after RIC allo-SCT, did not significant-
ly affect relapse. Taken together the results suggest that
prophylactic TKIs may improve outcome, but further con-
firmation is needed. However, patients we identified as
high risk for relapse (higher WBC, an RIC regimen, and
matched sibling donor SCT) might especially benefit from
post-transplant TKI.  Despite the potential of RIC regimen
recipients to relapse, we found no difference in OS and LFS
between patients who received an RIC regimen or a MAC
regimen. This confirms that RIC is a valid option for
patients ineligible for MAC, as shown by Bachanova et al.46
Interestingly, pre-transplant TKI was associated with a
higher cumulative incidence of aGvHD [37% (95%CI:
31%-41%) vs. 24% (95%CI: 15%-34%); P=0.04] in uni-
variate analysis. Although imatinib can be beneficial in
steroid-refractory cGvHD,48,49 the main imatinib side-
effects are edema, skin rashes and diarrhea.50 The patho-
physiology of these manifestations is still unknown. We
can hypothesize that the association of TKIs and
chemotherapy before HSCT can be deleterious and induce
primary lesions. However, TKI pre-transplant was not
associated with aGvHD in multivariate analysis (HR=1.52;
95%CI: 0.92-2.52; P=0.010). Whether TKIs are or are not
deleterious when used before transplantation deserves fur-
ther investigation. In multivariate analysis, TKIs post-
HSCT were associated with a lower incidence of GvHD.
This interesting issue of the potential beneficial impact of
TKIs post transplant will need to be confirmed since the
bias of patient selection by the physician for giving TKIs
may have interfered with this result. 
In conclusion, over the past decade, TKI administration
before allo-SCT has significantly improved the long-term
allo-SCT outcome of adult Ph+ALL. Prospective studies
will be of great interest to further confirm the potential
benefit of the prophylactic use of TKIs in the post-trans-
plant setting.
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